Morbidity and Mortality Weekly Report: MMWR, Volume 33U.S. Department of Health, Education, and Welfare, Public Health Service, Center for Disease Control, 1983 |
From inside the book
Results 6-10 of 100
Page 386
... Okla . 85 62 0921125 2311 20 10 49 25 10 12 5 2 21 10 2 31 10 4 12 5 1 15 3 3 849-3065-3 2- ~~~ ' ~ ' M ~~~ O ~ ♡ ~ 43 3 6 1 3 4 1 2 3 1 1 3 3 5 5 5 4 10 4 1 1 1 41 1 5 3 2 1 3 4 6 1 2 6 2 9 3 1 2 8 E.N. CENTRAL 1,774 1,123 408 127 60 ...
... Okla . 85 62 0921125 2311 20 10 49 25 10 12 5 2 21 10 2 31 10 4 12 5 1 15 3 3 849-3065-3 2- ~~~ ' ~ ' M ~~~ O ~ ♡ ~ 43 3 6 1 3 4 1 2 3 1 1 3 3 5 5 5 4 10 4 1 1 1 41 1 5 3 2 1 3 4 6 1 2 6 2 9 3 1 2 8 E.N. CENTRAL 1,774 1,123 408 127 60 ...
Page 403
... Okla Tex 4 10 1 6,343 7,827 6 5 1 1 93 18 1 33.439 41,784 5 3 MOUNTAIN Mont Idaho 32 32 7 17 13,752 14,594 28 29 3 578 635 663 662 Wyo Colo N Mex 1 19 402 384 3,979 4,110 6 6 1,548 1,771 1 Ariz Utah Nev 633 3,753 4,073 13 10 667 2,162 ...
... Okla Tex 4 10 1 6,343 7,827 6 5 1 1 93 18 1 33.439 41,784 5 3 MOUNTAIN Mont Idaho 32 32 7 17 13,752 14,594 28 29 3 578 635 663 662 Wyo Colo N Mex 1 19 402 384 3,979 4,110 6 6 1,548 1,771 1 Ariz Utah Nev 633 3,753 4,073 13 10 667 2,162 ...
Page 404
... Okla . Tex . MOUNTAIN Mont . Idaho Wyo . Colo N. Mex . N - O NOG , w 34 362 22 5 5 24 362 2176 70 184 105 10 27 GO NOÑOW WINN NNW B 49 1 2 27 13 27 15 2 17 1 W1IVO , AND CONG . Ñ.8 80 63 1 28 9 22 4 5 1 821 886 30 12 11 1 3 5 3 2 48 21 ...
... Okla . Tex . MOUNTAIN Mont . Idaho Wyo . Colo N. Mex . N - O NOG , w 34 362 22 5 5 24 362 2176 70 184 105 10 27 GO NOÑOW WINN NNW B 49 1 2 27 13 27 15 2 17 1 W1IVO , AND CONG . Ñ.8 80 63 1 28 9 22 4 5 1 821 886 30 12 11 1 3 5 3 2 48 21 ...
Page 405
... Okla . 121 121 127 126 13 6033 Tex 2,676 3,323 861 911 6221 91726 5 34 18 35865 136 35 56 45 MOUNTAIN 336 375 289 340 15 Mont 2 5 14 34 Idaho 14 6 18 18 48 d Wyo . 4 7 8 Colo 78 81 25 33 N Mex . 44 115 56 72 Ariz 131 90 133 136 Utah 11 ...
... Okla . 121 121 127 126 13 6033 Tex 2,676 3,323 861 911 6221 91726 5 34 18 35865 136 35 56 45 MOUNTAIN 336 375 289 340 15 Mont 2 5 14 34 Idaho 14 6 18 18 48 d Wyo . 4 7 8 Colo 78 81 25 33 N Mex . 44 115 56 72 Ariz 131 90 133 136 Utah 11 ...
Page 406
... Okla 70 48 12 2 0543064047025 8 21 8 13 722 / 764-53323 11 38 88 13 44354 3 1 EN CENTRAL 2,247 1,396 531 161 77 82 Akron , Ohio 57 31 15 Canton , Ohio 40 30 Chicago , Ill 547 305 153 563 42 822 8 2 19 28 Cincinnati , Ohio 115 80 19 9 ...
... Okla 70 48 12 2 0543064047025 8 21 8 13 722 / 764-53323 11 38 88 13 44354 3 1 EN CENTRAL 2,247 1,396 531 161 77 82 Akron , Ohio 57 31 15 Canton , Ohio 40 30 Chicago , Ill 547 305 153 563 42 822 8 2 19 28 Cincinnati , Ohio 115 80 19 9 ...
Other editions - View all
Common terms and phrases
Acquired Immunodeficiency Syndrome age group Alaska animal antibody Ariz Calif cancer Centers for Disease City Civilian clinical Colo Congenital rubella syndrome Conn cryptosporidiosis death Department of Health Disease Control E.S. CENTRAL Editorial Note Encephalitis Epidemiologic exposure Gonorrhea Guam Hawaii hemophilia Hepatitis hospital human illness immunization Immunodeficiency Syndrome AIDS increased infants infection influenza isolates Kans Legionellosis Leptospirosis lowa Malaria Mass measles MID ATLANTIC Minn MMWR Mortality Weekly Report Mumps Nebr NIOSH occurred Ohio Okla Oreg outbreak Pa.t Pac Trust Terr PACIFIC patients persons Pertussis Poliomyelitis population Primary & Secondary Psittacosis Public Health rabies Reporting Area risk RMSF Rubella specified notifiable diseases surveillance symptoms Syphilis Tenn tick-borne Total Toxic Shock syndrome Trichinosis Tuberculosis Tularemia Typhus fever U.S. Government Printing Unavailable TABLE United Upstate Utah vaccine Viral virus Wash weeks ending WN CENTRAL
Popular passages
Page 11 - National Center for Health Statistics. NCHS growth curves for children birth- 18 years. United States. Rockville, MD: National Center for Health Statistics. 1977. (Vital and health statistics. Series 1 1: Data from the National Health Survey, no.
Page 397 - Corticosteroids, other immunosuppressive agents, and immunosuppressive illnesses can interfere with the development of active immunity and predispose the patient to developing rabies. Immunosuppressive agents should not be administered during postexposure therapy, unless essential for the treatment of other conditions. When rabies post-exposure prophylaxis is administered to persons receiving steroids or other immunosuppressive therapy, it is especially important that serum be tested for rabies antibody...
Page 633 - ... authority to convey the warnings to the vaccinee, parent, guardian, or other responsible person of the possibility of vaccine-associated paralysis, particularly to susceptible family members and other close personal contacts. The Centers for Disease Control report that during 1972 to 1983, approximately 278.8 million OPV doses were distributed in the United States. During this same period, 87 vaccine-associated cases in apparently immunologically normal individuals were reported. Thirty-two occurred...
Page 397 - Two cases of neurologic illness resembling Guillain-Barre syndrome*'* a transient neuroparalytic illness, that resolved without sequelae in 12 weeks and a focal subacute central nervous system disorder temporally associated with HDCV, have been reported.
Page 437 - In: Remington JS, Klein JO, eds. Infectious diseases of the fetus and newborn infant. Philadelphia: WB Saunders, 1983:636-678.
Page 597 - Human cryptosporidiosis in immunocompetent and immunodeficient persons: studies of an outbreak and experimental transmission.
Page 397 - Once initiated, rabies prophylaxis should not be interrupted or discontinued because of local or mild systemic adverse reactions to rabies vaccine. Usually such reactions can be successfully managed with anti-inflammatory and antipyretic agents (eg aspirin). Reactions after vaccination with HDCV are less common than with previously available vaccines.
Page 398 - ... Category C. Animal reproduction studies have not been conducted with IMOVAX RABIES Vaccine. It is also not known whether the product can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Rabies vaccine should be given to a pregnant woman only if clearly needed. Because of the potential consequences of inadequately treated rabies exposure and limited data that indicate that fetal abnormalities have not been associated with rabies vaccination, pregnancy...
Page 557 - Hypertension detection and follow-up program cooperative group. Fiveyear findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension.
Page 392 - ... bite a person should be captured and observed for symptoms of rabies for 10 days. If symptoms do not develop, the animal may be assumed to be non-rabid. If the animal dies or is killed, its head, undamaged, should be sent promptly, under refrigeration but not frozen, to a public health laboratory. Any wild animal that bites or scratches a person should be killed at once and the head kept under refrigeration during transportation to a public health laboratory. Rubber gloves should be worn by the...